Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comprehensive proteomics metadata and integrative web portals facilitate sharing and integration of LINCS multiomics data.
Mol Cell Proteomics
March 2025
PCCSE, Department of Genome Sciences, University of Washington, Seattle, WA 98195. Electronic address:
The Library of Integrated Network-based Cellular Signatures (LINCS), an NIH Common Fund program, has cataloged and analyzed cellular function and molecular activity profiles in response to >80,000 perturbing agents that are potentially disruptive to cells. Because of the importance of proteins and their modifications to the response of specific cellular perturbations, four of the six LINCS centers have included significant proteomics efforts in the characterization of the resulting phenotype. This manuscript aims to describe this effort and the data harmonization and integration of the LINCS proteomics data discussed in recent LINCS papers.
View Article and Find Full Text PDFA Novel Methodology for Establishing MCID and SCB Thresholds for Patient-Reported Outcome Measures Following Reverse Total Shoulder Arthroplasty.
J Shoulder Elbow Surg
March 2025
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Increasing reliance on Patient Reported Outcome Measures (PROMs) following Reverse Total Shoulder Arthroplasty (rTSA) has resulted in variability in the thresholds for minimum clinically important difference (MCID) and substantial clinical benefit (SCB) reported in the literature. In this study, we aimed to identify the best threshold values for MCID and SCB for common rTSA PROMs.
Methods: The PubMed, Embase, MEDLINE, Cochrane Library, and Google Scholar databases were queried for studies published from January 1, 2000-March 1, 2024 that identified clinically significant thresholds for PROMs following rTSA.
Targeting quorum sensing in Pseudomonas aeruginosa with high-affinity inhibitors: A high-throughput screening and in-silico analysis.
Comput Biol Chem
March 2025
Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan.
Pseudomonas aeruginosa is a major pathogen in clinical settings, notorious for its intrinsic resistance to multiple antibiotics and ability to form biofilms, therefore, complicating treatment. This study reporting the results of a high-throughput screen of an antibacterial library targeting LasR, a key QS regulator in P. aeruginosa MB638, isolated from an infected surgical implant.
View Article and Find Full Text PDFDevelopment and Characterization of the [Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.
Mol Pharm
March 2025
Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China.
Cadherin 17 (CDH17) is highly expressed in digestive system cancers, and the potential of nanobodies targeting CDH17 as imaging probes and delivery vehicles for radioactive β-particles warrants exploration for their theranostic potential in CDH17-overexpressing gastric cancer (GC). In this study, we screened an anti-CDH17 nanobody library and constructed two antibodies: anti-CDH17 VHH (recombinant nanobody fused with a polyhistidine tag) and anti-CDH17 VHH-ABD (recombinant nanobody fused with an albumin-binding domain). VHH targeting CDH17 and its derivative VHH-ABD were conjugated with DOTA and labeled with radionuclide Lu.
View Article and Find Full Text PDFBalancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.
BMC Med Ethics
March 2025
Department of Genetics, Wyss Institute for Biologically Inspired Engineering at Harvard & Harvard Medical School, Boston, MA, USA.
Background: Sickle cell disease (SCD) and Diamond-Blackfan anemia syndrome (DBAS) are two hereditary blood diseases that present significant challenges to patients, their caregivers, and the healthcare system. Both conditions cause severe health complications and have limited treatment options, leaving many individuals without access to curative therapies like hematopoietic stem cell transplantation. Recent advancements in gene and cell therapies offer the potential for a new curative option, marking a pivotal shift in the management of these debilitating diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!